Kohei shitara (@KoheiShitara) / X

Gastric cancer, Targeting the tumor microenvironment

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Kohei shitara (@KoheiShitara) / X

ASCO #GI22: Gastric and esophageal cancers, HER2-targeted therapy, immunotherapy, ADCs

Sav Brar (@savbrar) / X

Angelica Petrillo (@AngelicaSSophie) / X

Kohei Shitara - Staff Doctor, Chiba, Japan

Kohei shitara (@KoheiShitara) / X

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Kohei shitara (@KoheiShitara) / X

Kohei Shitara, Videos & Research

Kohei Shitara, MD @KoheiShitara @theNCI @NCIResearchCtr #ASCOGI21 #GastrointestalCancer #GICancer #Cancer #Research P

PD-1 Inhibitors for Advanced Gastroesophageal Cancer

Kohei shitara (@KoheiShitara) / X

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)